ID   ADDG_RAT                Reviewed;         705 AA.
AC   Q62847; D3ZCH7; G3V9D7;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   12-OCT-2022, sequence version 3.
DT   24-JUL-2024, entry version 152.
DE   RecName: Full=Gamma-adducin {ECO:0000303|PubMed:7592723};
DE   AltName: Full=Adducin-like protein 70;
DE   AltName: Full=Protein kinase C-binding protein 35H {ECO:0000303|PubMed:7592723};
GN   Name=Add3;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), SUBUNIT, INTERACTION WITH ADD1, AND
RP   SUBCELLULAR LOCATION.
RC   STRAIN=Sprague-Dawley; TISSUE=Kidney;
RX   PubMed=7592723; DOI=10.1074/jbc.270.43.25534;
RA   Dong L., Chapline C., Mousseau B., Fowler L., Ramsay K., Stevens J.L.,
RA   Jaken S.;
RT   "35H, a sequence isolated as a protein kinase C binding protein, is a novel
RT   member of the adducin family.";
RL   J. Biol. Chem. 270:25534-25540(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), TISSUE SPECIFICITY, AND VARIANT
RP   GLN-572.
RC   STRAIN=Milan {ECO:0000303|PubMed:9299427};
RX   PubMed=9299427; DOI=10.1006/bbrc.1997.7173;
RA   Tripodi G., Szpirer C., Reina C., Szpirer J., Bianchi G.;
RT   "Polymorphism of gamma-adducin gene in genetic hypertension and mapping of
RT   the gene to rat chromosome 1q55.";
RL   Biochem. Biophys. Res. Commun. 237:685-689(1997).
RN   [3] {ECO:0000312|Proteomes:UP000002494}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Brown Norway {ECO:0000312|Proteomes:UP000002494};
RX   PubMed=15057822; DOI=10.1038/nature02426;
RA   Gibbs R.A., Weinstock G.M., Metzker M.L., Muzny D.M., Sodergren E.J.,
RA   Scherer S., Scott G., Steffen D., Worley K.C., Burch P.E., Okwuonu G.,
RA   Hines S., Lewis L., Deramo C., Delgado O., Dugan-Rocha S., Miner G.,
RA   Morgan M., Hawes A., Gill R., Holt R.A., Adams M.D., Amanatides P.G.,
RA   Baden-Tillson H., Barnstead M., Chin S., Evans C.A., Ferriera S.,
RA   Fosler C., Glodek A., Gu Z., Jennings D., Kraft C.L., Nguyen T.,
RA   Pfannkoch C.M., Sitter C., Sutton G.G., Venter J.C., Woodage T., Smith D.,
RA   Lee H.-M., Gustafson E., Cahill P., Kana A., Doucette-Stamm L.,
RA   Weinstock K., Fechtel K., Weiss R.B., Dunn D.M., Green E.D.,
RA   Blakesley R.W., Bouffard G.G., De Jong P.J., Osoegawa K., Zhu B., Marra M.,
RA   Schein J., Bosdet I., Fjell C., Jones S., Krzywinski M., Mathewson C.,
RA   Siddiqui A., Wye N., McPherson J., Zhao S., Fraser C.M., Shetty J.,
RA   Shatsman S., Geer K., Chen Y., Abramzon S., Nierman W.C., Havlak P.H.,
RA   Chen R., Durbin K.J., Egan A., Ren Y., Song X.-Z., Li B., Liu Y., Qin X.,
RA   Cawley S., Cooney A.J., D'Souza L.M., Martin K., Wu J.Q.,
RA   Gonzalez-Garay M.L., Jackson A.R., Kalafus K.J., McLeod M.P.,
RA   Milosavljevic A., Virk D., Volkov A., Wheeler D.A., Zhang Z., Bailey J.A.,
RA   Eichler E.E., Tuzun E., Birney E., Mongin E., Ureta-Vidal A., Woodwark C.,
RA   Zdobnov E., Bork P., Suyama M., Torrents D., Alexandersson M., Trask B.J.,
RA   Young J.M., Huang H., Wang H., Xing H., Daniels S., Gietzen D., Schmidt J.,
RA   Stevens K., Vitt U., Wingrove J., Camara F., Mar Alba M., Abril J.F.,
RA   Guigo R., Smit A., Dubchak I., Rubin E.M., Couronne O., Poliakov A.,
RA   Huebner N., Ganten D., Goesele C., Hummel O., Kreitler T., Lee Y.-A.,
RA   Monti J., Schulz H., Zimdahl H., Himmelbauer H., Lehrach H., Jacob H.J.,
RA   Bromberg S., Gullings-Handley J., Jensen-Seaman M.I., Kwitek A.E.,
RA   Lazar J., Pasko D., Tonellato P.J., Twigger S., Ponting C.P., Duarte J.M.,
RA   Rice S., Goodstadt L., Beatson S.A., Emes R.D., Winter E.E., Webber C.,
RA   Brandt P., Nyakatura G., Adetobi M., Chiaromonte F., Elnitski L.,
RA   Eswara P., Hardison R.C., Hou M., Kolbe D., Makova K., Miller W.,
RA   Nekrutenko A., Riemer C., Schwartz S., Taylor J., Yang S., Zhang Y.,
RA   Lindpaintner K., Andrews T.D., Caccamo M., Clamp M., Clarke L., Curwen V.,
RA   Durbin R.M., Eyras E., Searle S.M., Cooper G.M., Batzoglou S., Brudno M.,
RA   Sidow A., Stone E.A., Payseur B.A., Bourque G., Lopez-Otin C., Puente X.S.,
RA   Chakrabarti K., Chatterji S., Dewey C., Pachter L., Bray N., Yap V.B.,
RA   Caspi A., Tesler G., Pevzner P.A., Haussler D., Roskin K.M., Baertsch R.,
RA   Clawson H., Furey T.S., Hinrichs A.S., Karolchik D., Kent W.J.,
RA   Rosenbloom K.R., Trumbower H., Weirauch M., Cooper D.N., Stenson P.D.,
RA   Ma B., Brent M., Arumugam M., Shteynberg D., Copley R.R., Taylor M.S.,
RA   Riethman H., Mudunuri U., Peterson J., Guyer M., Felsenfeld A., Old S.,
RA   Mockrin S., Collins F.S.;
RT   "Genome sequence of the Brown Norway rat yields insights into mammalian
RT   evolution.";
RL   Nature 428:493-521(2004).
RN   [4] {ECO:0000312|EMBL:EDL94414.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Brown Norway {ECO:0000312|EMBL:EDL94414.1};
RX   PubMed=15632090; DOI=10.1101/gr.2889405;
RA   Florea L., Di Francesco V., Miller J., Turner R., Yao A., Harris M.,
RA   Walenz B., Mobarry C., Merkulov G.V., Charlab R., Dew I., Deng Z.,
RA   Istrail S., Li P., Sutton G.;
RT   "Gene and alternative splicing annotation with AIR.";
RL   Genome Res. 15:54-66(2005).
RN   [5]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-423; SER-583; SER-585;
RP   SER-672; SER-676 AND SER-680, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
RN   [6]
RP   FUNCTION, AND DISRUPTION PHENOTYPE.
RX   PubMed=27927653; DOI=10.1152/ajprenal.00529.2016;
RA   Fan F., Pabbidi M.R., Ge Y., Li L., Wang S., Mims P.N., Roman R.J.;
RT   "Knockdown of Add3 impairs the myogenic response of renal afferent
RT   arterioles and middle cerebral arteries.";
RL   Am. J. Physiol. 312:F971-F981(2017).
RN   [7]
RP   FUNCTION, TISSUE SPECIFICITY, AND DISRUPTION PHENOTYPE.
RX   PubMed=32830539; DOI=10.1152/ajprenal.00239.2020;
RA   Fan L., Gao W., Nguyen B.V., Jefferson J.R., Liu Y., Fan F., Roman R.J.;
RT   "Impaired renal hemodynamics and glomerular hyperfiltration contribute to
RT   hypertension-induced renal injury.";
RL   Am. J. Physiol. 319:F624-F635(2020).
RN   [8]
RP   FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, DISRUPTION PHENOTYPE,
RP   VARIANT GLN-572, AND CHARACTERIZATION OF VARIANT GLN-572.
RX   PubMed=32029431; DOI=10.1681/asn.2019080784;
RA   Fan F., Geurts A.M., Pabbidi M.R., Ge Y., Zhang C., Wang S., Liu Y.,
RA   Gao W., Guo Y., Li L., He X., Lv W., Muroya Y., Hirata T., Prokop J.,
RA   Booz G.W., Jacob H.J., Roman R.J.;
RT   "A Mutation in gamma-Adducin Impairs Autoregulation of Renal Blood Flow and
RT   Promotes the Development of Kidney Disease.";
RL   J. Am. Soc. Nephrol. 31:687-700(2020).
RN   [9]
RP   FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=33308016; DOI=10.1152/ajprenal.00423.2020;
RA   Gao W., Liu Y., Fan L., Zheng B., Jefferson J.R., Wang S., Zhang H.,
RA   Fang X., Nguyen B.V., Zhu T., Roman R.J., Fan F.;
RT   "Role of gamma-adducin in actin cytoskeleton rearrangements in podocyte
RT   pathophysiology.";
RL   Am. J. Physiol. 320:F97-F113(2021).
RN   [10]
RP   FUNCTION, AND DISRUPTION PHENOTYPE.
RX   PubMed=33414130; DOI=10.1124/jpet.120.000408;
RA   Fan L., Gao W., Liu Y., Jefferson J.R., Fan F., Roman R.J.;
RT   "Knockout of gamma-Adducin Promotes NG-Nitro-L-Arginine-Methyl-Ester-
RT   Induced Hypertensive Renal Injury.";
RL   J. Pharmacol. Exp. Ther. 377:189-198(2021).
CC   -!- FUNCTION: Membrane-cytoskeleton-associated protein that promotes the
CC       assembly of the spectrin-actin network. Plays a role in actin filament
CC       capping. Binds to calmodulin (By similarity). Involved in myogenic
CC       reactivity of the renal afferent arteriole (Af-art), renal interlobular
CC       arteries and middle cerebral artery (MCA) to increased perfusion
CC       pressure (PubMed:27927653, PubMed:32029431, PubMed:32830539). Involved
CC       in regulation of potassium channels in the vascular smooth muscle cells
CC       (VSMCs) of the Af-art and MCA ex vivo (PubMed:27927653,
CC       PubMed:32029431). Involved in regulation of glomerular capillary
CC       pressure, glomerular filtration rate (GFR) and glomerular nephrin
CC       expression in response to hypertension (PubMed:32830539,
CC       PubMed:33414130). Involved in renal blood flow (RBF) autoregulation
CC       (PubMed:32029431, PubMed:32830539, PubMed:33414130). Plays a role in
CC       podocyte structure and function. Regulates globular monomer actin (G-
CC       actin) and filamentous polymer actin (F-actin) ratios in the primary
CC       podocytes affecting actin cytoskeleton organization. Regulates
CC       expression of synaptopodin, RhoA, Rac1 and CDC42 in the renal cortex
CC       and the primary podocytes. Regulates expression of nephrin in the
CC       glomeruli and in the primary podocytes, expression of nephrin and
CC       podocinin in the renal cortex, and expression of focal adhesion
CC       proteins integrin alpha-3 and integrin beta-1 in the glomeruli.
CC       Involved in cell migration and cell adhesion of podocytes, and in
CC       podocyte foot process effacement (PubMed:33308016). Regulates
CC       expression of profibrotics markers MMP2, MMP9, TGF beta-1, tubular
CC       tight junction protein E-cadherin, and mesenchymal markers vimentin and
CC       alpha-SMA (PubMed:33414130). Promotes the growth of neurites (By
CC       similarity). {ECO:0000250|UniProtKB:Q9QYB5,
CC       ECO:0000250|UniProtKB:Q9UEY8, ECO:0000269|PubMed:27927653,
CC       ECO:0000269|PubMed:32029431, ECO:0000269|PubMed:32830539,
CC       ECO:0000269|PubMed:33308016, ECO:0000269|PubMed:33414130}.
CC   -!- SUBUNIT: Heterodimer of an alpha and a gamma subunit.
CC       {ECO:0000269|PubMed:7592723}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton
CC       {ECO:0000269|PubMed:7592723}. Cell membrane
CC       {ECO:0000269|PubMed:32029431, ECO:0000269|PubMed:33308016}; Peripheral
CC       membrane protein; Cytoplasmic side. Cytoplasm
CC       {ECO:0000250|UniProtKB:Q9QYB5}. Note=Full-length protein and the
CC       cleavage fragment 358-706 localize mainly to the cytoplasm, while
CC       cleavage fragment 1-357 translocates from the cytoplasm to the nucleus.
CC       {ECO:0000250|UniProtKB:Q9QYB5}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC         Comment=Additional isoforms seem to exist.;
CC       Name=2; Synonyms=Long;
CC         IsoId=Q62847-1; Sequence=Displayed;
CC       Name=1; Synonyms=Short;
CC         IsoId=Q62847-2; Sequence=VSP_000190;
CC   -!- TISSUE SPECIFICITY: [Isoform 2]: Expressed in kidney, brain, spleen,
CC       liver and heart. {ECO:0000269|PubMed:9299427}.
CC   -!- TISSUE SPECIFICITY: [Isoform 1]: Expressed in kidney, brain, spleen,
CC       liver and heart. {ECO:0000269|PubMed:9299427}.
CC   -!- TISSUE SPECIFICITY: Expressed in renal interlobular arteries,
CC       afferent/efferent arterioles, parietal glomerular epithelial cells and
CC       microvilli of the luminal surface of the proximal tubule (at protein
CC       level) (PubMed:32830539). Expressed in podocytes (at protein level)
CC       (PubMed:32830539, PubMed:33308016) Expressed in renal cortex (at
CC       protein level) (PubMed:32029431, PubMed:32830539, PubMed:33308016).
CC       Expressed in primary vascular smooth muscle cells (VSMCs) of the kidney
CC       (at protein level) (PubMed:32029431). Expressed in tubular cells and
CC       glomeruli (at protein level) (PubMed:33308016).
CC       {ECO:0000269|PubMed:32029431, ECO:0000269|PubMed:32830539,
CC       ECO:0000269|PubMed:33308016}.
CC   -!- DOMAIN: Comprised of three regions: a N-terminal protease-resistant
CC       globular head region, a short connecting subdomain, and a protease-
CC       sensitive tail region.
CC   -!- PTM: Sumoylated. {ECO:0000250}.
CC   -!- PTM: Proteolytically cleaved by asparagine endopeptidase (AEP) into 2
CC       fragments. Overexpression of the 1-357 fragment induces neuronal
CC       apoptosis, and overexpression of either 1-357 or 358-706 fragment
CC       increases the degeneration of dendritic spines. Overexpression of the
CC       1-357 fragment impairs neurite outgrowth by downregulating the
CC       expression of Rac2, and induces synaptic dysfunction and cognitive
CC       impairments in tau P301S transgenic mice, a mouse model for Alzheimer
CC       disease (AD). {ECO:0000250|UniProtKB:Q9QYB5}.
CC   -!- DISRUPTION PHENOTYPE: Renal afferent arteriole (Af-art) of the Dicer-
CC       substrate short interfering RNA (DsiRNA) knockdown rats dilates instead
CC       of constricts as the wild-type vessel in response to an elevation in
CC       perfusion pressure. Knockdown results in impaired myogenic response in
CC       the middle cerebral artery (MCA), but vasoconstrictor response to
CC       serotonin is not affected in the presence of iberiotoxin (IBTX).
CC       Knockdown has no effect on the vasoconstrictor response of the renal
CC       Af-art to norepinephrine. Smooth muscle cells isolated from the renal
CC       microvessels or MCAs of the knockdown rats have higher peak potassium
CC       currents than the wild-type cells. A significantly higher level of
CC       IBTX-sensitive peak potassium current densities are detected in smooth
CC       muscle cells of the cerebral microvessels of the knockdown rats
CC       (PubMed:27927653). Knockout rats have elevated iberiotoxin-sensitive
CC       potassium (BK) channel current in renal vascular smooth muscle cells
CC       (VSMCs) and exhibit impairments in the myogenic response of Af-arts
CC       (PubMed:32029431). Renal blood flow (RBF) autoregulation is also
CC       impaired (PubMed:32029431, PubMed:32830539). Knockout rats have
CC       decreased glomerular capillary pressure in response to elevated blood
CC       pressure. After 1 week of DOCA-salt induced hypertension the glomerular
CC       filtration rate (GFR) increases and glomerular nephrin expression
CC       decreases while they remain unchanged in wild-type rats. Myogenic
CC       response is impaired in interlobular arteries of the knockout rats.
CC       Proteinuria, glomerulosclerosis and renal interstitial fibrosis are
CC       more pronounced in knockout rats after 3 weeks of hypertension compared
CC       to wild-type rats. Expression of macrophage-related proinflammatory
CC       cytokines, infiltrating CD68(+) macrophages and the markers of
CC       epithelial mesenchymal transition increase after hypertension. These
CC       alterations in hypertensive knockout rats lead to increased
CC       transmission of pressure to glomeruli inducing podocyte loss, and
CC       accelerated progression of chronic kidney disease (CKD)
CC       (PubMed:32830539). Acute administration of N(G)-nitro-L-arginine methyl
CC       ester (L-NAME) raises mean arterial pressure (MAP) of the knockout rats
CC       as in wild-type, but RBF and GFR are decreased less in knockout rats.
CC       However, RBF and GFR are significantly greater in knockout rats than in
CC       wild-type after the simultaneous administration of L-NAME and
CC       furosemide. Chronic administration of L-NAME with a simultaneous high-
CC       salt diet leads to impaired renal vasoconstrictor response to the
CC       blockade of nitric oxide synthase, which promotes hypertension-induced
CC       proteinuria and renal injury in knockout rats. After chronic
CC       administration of L-NAME, MAP increases in the knockout rats the same
CC       way as in wild-type, but RBF, GFR and glomerular capillary pressure are
CC       increased. They have greater loss of podocytes and glomerular nephrin
CC       expression than wild-type rats, and increased renal interstitial
CC       fibrosis. Expression of the profibrotics markers MMP9, MMP2 and TGF
CC       beta-1 increases more in L-NAME-treated knockout rats than in wild-type
CC       rats. Expression of tubular tight junction protein E-cadherin decreases
CC       more in knockout rats treated with L-NAME and high-salt diet for 3
CC       weeks in association with greater expression of mesenchymal markers
CC       vimentin and alpha-SMA compared to wild-type (PubMed:33414130).
CC       {ECO:0000269|PubMed:27927653, ECO:0000269|PubMed:32029431,
CC       ECO:0000269|PubMed:32830539, ECO:0000269|PubMed:33414130}.
CC   -!- SIMILARITY: Belongs to the aldolase class II family. Adducin subfamily.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U35775; AAC52277.1; -; mRNA.
DR   EMBL; CH473986; EDL94414.1; -; Genomic_DNA.
DR   EMBL; CH473986; EDL94415.1; -; Genomic_DNA.
DR   EMBL; CH473986; EDL94416.1; -; Genomic_DNA.
DR   RefSeq; NP_001157575.1; NM_001164103.1. [Q62847-1]
DR   RefSeq; NP_113740.2; NM_031552.2. [Q62847-2]
DR   RefSeq; XP_006231661.1; XM_006231599.3. [Q62847-1]
DR   RefSeq; XP_006231662.1; XM_006231600.3. [Q62847-1]
DR   RefSeq; XP_006231663.1; XM_006231601.3. [Q62847-1]
DR   RefSeq; XP_006231664.1; XM_006231602.3.
DR   RefSeq; XP_008758732.1; XM_008760510.2. [Q62847-1]
DR   AlphaFoldDB; Q62847; -.
DR   SMR; Q62847; -.
DR   BioGRID; 247271; 1.
DR   STRING; 10116.ENSRNOP00000043399; -.
DR   iPTMnet; Q62847; -.
DR   PhosphoSitePlus; Q62847; -.
DR   jPOST; Q62847; -.
DR   PaxDb; 10116-ENSRNOP00000043399; -.
DR   Ensembl; ENSRNOT00000017600.7; ENSRNOP00000017600.5; ENSRNOG00000012820.9. [Q62847-2]
DR   Ensembl; ENSRNOT00000044827.7; ENSRNOP00000043399.3; ENSRNOG00000012820.9. [Q62847-1]
DR   Ensembl; ENSRNOT00065018534; ENSRNOP00065014172; ENSRNOG00065011403. [Q62847-1]
DR   GeneID; 25230; -.
DR   KEGG; rno:25230; -.
DR   AGR; RGD:2043; -.
DR   CTD; 120; -.
DR   RGD; 2043; Add3.
DR   eggNOG; KOG3699; Eukaryota.
DR   GeneTree; ENSGT00940000155257; -.
DR   HOGENOM; CLU_006033_9_2_1; -.
DR   InParanoid; Q62847; -.
DR   OMA; XVRISKE; -.
DR   OrthoDB; 45123at2759; -.
DR   PhylomeDB; Q62847; -.
DR   TreeFam; TF313003; -.
DR   Reactome; R-RNO-5223345; Miscellaneous transport and binding events.
DR   Reactome; R-RNO-9013405; RHOD GTPase cycle.
DR   Reactome; R-RNO-9035034; RHOF GTPase cycle.
DR   PRO; PR:Q62847; -.
DR   Proteomes; UP000002494; Chromosome 1.
DR   Proteomes; UP000234681; Chromosome 1.
DR   Bgee; ENSRNOG00000012820; Expressed in spleen and 19 other cell types or tissues.
DR   GO; GO:0005903; C:brush border; ISO:RGD.
DR   GO; GO:0005938; C:cell cortex; ISO:RGD.
DR   GO; GO:0005911; C:cell-cell junction; ISO:RGD.
DR   GO; GO:0000794; C:condensed nuclear chromosome; ISO:RGD.
DR   GO; GO:0005737; C:cytoplasm; ISO:RGD.
DR   GO; GO:0005856; C:cytoskeleton; ISO:RGD.
DR   GO; GO:0016020; C:membrane; ISO:RGD.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0014069; C:postsynaptic density; ISO:RGD.
DR   GO; GO:0051015; F:actin filament binding; IBA:GO_Central.
DR   GO; GO:0005516; F:calmodulin binding; IEA:UniProtKB-KW.
DR   GO; GO:0005080; F:protein kinase C binding; IDA:RGD.
DR   GO; GO:0005200; F:structural constituent of cytoskeleton; ISO:RGD.
DR   GO; GO:0051016; P:barbed-end actin filament capping; IBA:GO_Central.
DR   GO; GO:0051495; P:positive regulation of cytoskeleton organization; IMP:RGD.
DR   GO; GO:0045907; P:positive regulation of vasoconstriction; IMP:RGD.
DR   GO; GO:0009410; P:response to xenobiotic stimulus; IDA:RGD.
DR   Gene3D; 3.40.225.10; Class II aldolase/adducin N-terminal domain; 1.
DR   InterPro; IPR051017; Aldolase-II_Adducin_sf.
DR   InterPro; IPR001303; Aldolase_II/adducin_N.
DR   InterPro; IPR036409; Aldolase_II/adducin_N_sf.
DR   PANTHER; PTHR10672; ADDUCIN; 1.
DR   PANTHER; PTHR10672:SF5; GAMMA-ADDUCIN; 1.
DR   Pfam; PF00596; Aldolase_II; 1.
DR   SMART; SM01007; Aldolase_II; 1.
DR   SUPFAM; SSF53639; AraD/HMP-PK domain-like; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Actin-binding; Alternative splicing; Calmodulin-binding;
KW   Cell membrane; Cytoplasm; Cytoskeleton; Isopeptide bond; Membrane;
KW   Phosphoprotein; Reference proteome; Ubl conjugation.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000250|UniProtKB:Q9UEY8"
FT   CHAIN           2..705
FT                   /note="Gamma-adducin"
FT                   /id="PRO_0000218538"
FT   REGION          1..22
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          472..495
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          535..556
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          572..612
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          658..705
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          683..700
FT                   /note="Interaction with calmodulin"
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        585..605
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        682..696
FT                   /note="Basic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   SITE            357
FT                   /note="Cleavage by asparagine endopeptidase (AEP)"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QYB5"
FT   MOD_RES         2
FT                   /note="N-acetylserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9UEY8"
FT   MOD_RES         31
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QYB5"
FT   MOD_RES         42
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9UEY8"
FT   MOD_RES         64
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9UEY8"
FT   MOD_RES         402
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9UEY8"
FT   MOD_RES         414
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QYB5"
FT   MOD_RES         423
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         442
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9UEY8"
FT   MOD_RES         461
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9UEY8"
FT   MOD_RES         583
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         585
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         590
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QYB5"
FT   MOD_RES         672
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         676
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         678
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QYB5"
FT   MOD_RES         680
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         682
FT                   /note="Phosphoserine; by PKC"
FT                   /evidence="ECO:0000250|UniProtKB:Q9UEY8"
FT   CROSSLNK        484
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:Q9UEY8"
FT   VAR_SEQ         578..609
FT                   /note="Missing (in isoform 1)"
FT                   /evidence="ECO:0000303|PubMed:7592723"
FT                   /id="VSP_000190"
FT   VARIANT         572
FT                   /note="K -> Q (in strain: Milan normotensive and FHH
FT                   hypertensive; no constriction of afferent arterioles in
FT                   response to increased pressure and impaired renal blood
FT                   flow autoregulation resulting in kidney disease in both
FT                   strains; redistributes from the cell membrane to
FT                   perinuclear location and disrupts the F-actin cytoskeleton
FT                   in the kidney and renal vascular smooth muscle cells of
FT                   FHH; elevated membrane expression of the iberiotoxin-
FT                   sensitive potassium channel alpha and elevated iberiotoxin-
FT                   sensitive potassium channel current in renal vascular
FT                   smooth muscle cells of FHH; proteinuria, renal interstitial
FT                   fibrosis, alterations in gromelural capillary pressure,
FT                   increased permeability to albumin and impaired glomerular
FT                   function in FHH after induction of hypertension)"
FT                   /evidence="ECO:0000269|PubMed:32029431,
FT                   ECO:0000269|PubMed:9299427"
FT   CONFLICT        5
FT                   /note="T -> S (in Ref. 1; AAC52277 and 2; no nucleotide
FT                   entry)"
FT   CONFLICT        47
FT                   /note="Q -> E (in Ref. 1; AAC52277 and 2; no nucleotide
FT                   entry)"
FT   CONFLICT        75
FT                   /note="I -> T (in Ref. 1; AAC52277 and 2; no nucleotide
FT                   entry)"
FT   CONFLICT        140
FT                   /note="K -> E (in Ref. 1; AAC52277 and 2; no nucleotide
FT                   entry)"
FT   CONFLICT        180
FT                   /note="S -> P (in Ref. 1; AAC52277 and 2; no nucleotide
FT                   entry)"
FT   CONFLICT        572
FT                   /note="K -> Q (in Ref. 1; AAC52277)"
FT   CONFLICT        701..705
FT                   /note="EKVEA -> GES (in Ref. 1; AAC52277)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   705 AA;  78818 MW;  F451D61B340A674C CRC64;
     MSSDTSQAVI TTPPPPSMPH KERYFDRINE SDPEYLRERN MSPDLRQDFN MMEQRKRVTQ
     ILQSPAFRED LECLIQEQMK KGHDPTGLLA LQQIADYIMA NSFTGFSSPP LSLGMVTPIN
     DLPGADTSSY VKGEKLTRCK LASLYRLADL FGWAHLANTY ISVRVSKEQD HIIIIPRGLS
     FSEATASALV KVNIIGEVVD QGSTNLKIDH SGFSPHAAIY STRPDVKCVI HIHTLATAAV
     SSMKCGILPI SQESLILGDV AYYDYQGSLD EEEERIELQK VLGPSCKVLV LRNHGVVALG
     ETLEEAFHYI FNVQMACEIQ VQAVAGAGGV DNLLILDLQK YKAFTHGVAM TGGGGVNMGS
     HQKWKVGEIE FEGLMRTLDN LGYRTGYAYR HPLVREKPRH KSDVEIPATV TAFSFEDDSV
     PLSPLKYMAQ RQQREKTRWL NSPNTYMKVN VPEESRNGET SPRTKITWMK AEDPSKVSSG
     TPIKIEDPNQ FVPLNTNPTE VLEKRNKIRE QNRYDLKTAG PQSQLLAGIV VDKPPSTMRF
     EDDDQGPPAP PNPFSHLMEG ELEEYTKTIE RKQQGLDDAE QESLSDDAAS VSQIQSQTQS
     PQSVPERLEE NHELFSKSFT SVDVPVIVNG KDEMHDVEDE LAQRVSRLTT STTIENIEIT
     IKSPDRTEEV LSPDGSPSKS PSKKKKKFRT PSFLKKNKKK EKVEA
//
